U.S. to resume J&J COVID-19 vaccinations despite rare clot risk
The HinduU.S. health officials lifted an 11-day pause on COVID-19 vaccinations using Johnson & Johnson's single-dose shot, after scientific advisers decided its benefits outweigh a rare risk of blood clot. But ultimately Friday, the Food and Drug Administration and Centers for Disease Control and Prevention decided that J&J's one-and-done vaccine is critical to fight the pandemic — and that the small clot risk could be handled with warnings to help younger women decide if they should use that shot or an alternative. The US decision — similar to how European regulators are rolling out J&J's shot — comes after CDC advisers earlier Friday voted 10-4 to resume vaccinations but panelists made clear that they must come with warnings about the risk. It does not absolve us from making sure that people who receive this vaccine, if they are in the risk group, that we inform them of that.” European regulators earlier this week made a similar decision, deciding the clot risk was small enough to allow the rollout of J&J's shot.